Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002190 · ClinicalTrials.gov registry record · Phase 2
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002190 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 30 participants.
The verdict
NCT00002190, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002190
The ClinicalTrials.gov registry entry for NCT00002190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002190 about?
NCT00002190 is a clinical study titled "A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients". To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
What is the current status of trial NCT00002190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00002190?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002190?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.